IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell rating on IGMS stock.

In yet another early year blow for the Bay Area’s biotech workforce, IGM Biosciences is laying off almost three-fourths of ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates, imvotamab and IGM-2644, in the wake of disappointing data. The biotech ...

The job cuts reflect the normal maturation of companies such as Alameda-based Scribe, which is moving from a preclinical to ...

The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

Total means the test detects both types of antibodies that occur in response to HAV, including immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. A total reactive result means the HAV ...

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...

“I want to thank our colleagues who will be departing from IGM as part of the restructuring and acknowledge their many contributions to our programs,” added Dr. Harler. “We are grateful for ...